Viyash targets $1.5 billion ex-US companion-animal market from 2029
Key highlights
- Viyash targets close to $1.5 billion of companion-animal markets outside the US from calendar 2029.
- Three to four relevant products have current brand value of about $3 billion, which management expects could reach about $3.5 billion to $4 billion by FY30.
- Management cited potential 10% to 15% market share after generic entry and price erosion of about 40% to 60%.
- Viyash expects the Ambernath companion-animal facility to be ready in the first quarter of the following year.
powered by IRIS

Viyash Scientific Limited is targeting close to $1.5 billion of companion-animal markets outside the US as basic patents on relevant products expire in calendar 2029. Management said the opportunity is part of three to four products with current global brand value of about $3 billion, which it expects could rise to about $3.5 billion to $4 billion by FY30.
Know Viyash Scientific inside out
Results, valuation, peers and who's buying, in one view.
What is Viyash's 2029 companion-animal opportunity?
Viyash’s selected ex-US companion-animal market is close to $1.5 billion, within a broader group of products whose basic patents are due to expire in calendar 2029. Management said the three to four relevant products have combined brand value of about $3 billion across all markets today. The $1.5 billion figure represents only the countries Viyash is targeting and explicitly excludes the US.
Management expects the brand value of those three to four products to reach about $3.5 billion to $4 billion by FY30, before generic price reductions. It said patent expiry can also expand volumes. Viyash did not provide a revenue forecast for its own launches, but management used potential market share of 10% to 15% and price erosion of about 40% in its illustration, while also considering a 60% erosion case.
When can Viyash launch companion-animal generics?
Viyash expects the principal launches in calendar 2029 because the underlying basic patents are scheduled to expire that year. Management said some expiries may fall in February or March, placing their commercial effect in FY30. It also said country-level requirements differ, so a common patent-expiry year does not mean every market will have the same launch date.
The company’s stated strategy is to shift from launches of mature products to day-one generic launches. Management said this approach requires a longer gestation period and higher investment than its earlier animal-health activity, which had annual spending of about Rs 10 crore to Rs 12 crore and has increased to about Rs 40 crore. That investment is part of preparation for the 2029 opportunity rather than evidence of current sales from these products.
Management said local manufacturing could allow launches roughly nine to 12 months earlier in markets such as Brazil, Mexico and Turkey. The potential advantage comes from producing locally rather than relying entirely on exports. However, Viyash still described 2029 as the expected launch year for the larger products, making any earlier entry dependent on the individual market and manufacturing arrangement.
How is Viyash preparing its companion-animal supply chain?
Viyash is building a dedicated companion-animal facility at Ambernath because these products require different sizes, flavours, equipment standards and dedicated production compared with human tablets. Management expected the facility to be ready in the first quarter of the following year. The transcript did not disclose the plant’s capacity, project cost or revenue contribution.
The Ambernath site is intended to support Viyash’s fully integrated model, covering development, active pharmaceutical ingredient supply, finished formulations and regulatory filings. Management said many generic competitors have either a commercial front end or finished-product facilities in Europe. Viyash’s stated differentiation is to combine these functions, supporting supply-chain flexibility and longer-term launch capacity.
Viyash is also preparing a backup supply route through a Turkish partner facility that management expects to become Europe-approved around December or January. It plans to launch products in Turkey from that site if needed, including if an audit at the new Ambernath facility is delayed. Management said filings are not restricted by Ambernath’s construction because parallel manufacturing options are being developed.
Got a follow-up? Ask IRIS
How will acquisitions and overseas markets support Viyash's plan?
Viyash’s first acquisition priority is companion animals, with market access its main objective and product-gap filling a secondary consideration. Management said it does not need manufacturing-led acquisitions because it already has a large manufacturing base. Instead, it is evaluating in-licensed products and acquisitions that could add commercial infrastructure in target markets.
Management said it was continuously evaluating potential transactions and expected a sizable acquisition next year, although it cautioned that a deal might not occur within the next two quarters. Due diligence, market assessment and transaction structuring remain unresolved steps. This is management’s stated intention rather than a disclosed acquisition, valuation or commitment to complete a transaction.
Europe is Viyash’s nearer-term companion-animal focus, while Australia and Canada are being explored for registrations and commercial infrastructure after European product development and filings. Management said generic volume is more than 50% of the European market, compared with US genericisation of about 15% to 20%. It attributed Europe’s increase partly to post-COVID changes and said it expects European generic penetration could reach 70% to 80% in three to four years as larger launches arrive in 2029 and 2030.
The US is not included in the $1.5 billion target market. Management said it may become a key priority after two to three years, when it expects Viyash’s companion-animal supply chain to be more mature and US genericisation to improve. For now, its sequence is to pursue Europe and other immediate ex-US markets before committing resources to a larger US expansion.
Conclusion
Viyash’s companion-animal strategy is tied to a defined 2029 patent-expiry window: three to four products with current brand value of about $3 billion, of which close to $1.5 billion is in its selected markets outside the US. The plan combines day-one generic launches, local or dedicated manufacturing, product development and market-access acquisitions, rather than relying on near-term sales from the pipeline.
The next developments to watch are the Ambernath facility’s expected readiness in the first quarter of the following year, the Turkish partner site’s anticipated Europe approval around December or January, and management’s expectation of a sizable acquisition next year. Country-specific registrations, local manufacturing readiness and the February or March 2029 patent-expiry timing will determine when individual launches can begin.


